ZR-75-1 EGFR [ZR-HERc 1F)] cell line

Contributors

Inventor Institute
Lambert Dorssers Erasmus University Medical Center (Erasmus MC)
SKU: 154629
Product description: Breast cancer is widely and effectively treated with endocrine treatment. However, in many cases the tumours will eventually progress into an estrogen-independent and therapy-resistant phenotype.Seven genes including AKT1, AKT2, BCAR1, BCAR2, BCAR3, EGFR2 and GRB7 have been shown to directly underlie estrogen independence in human breast cancer cells. This cell line is part of a panel of 16 cell lines (Cat No 154621-154635, 154642) which have been transfected with these genes, plus the parental (Cat No 154547).This cell line is a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity
Alternate name: Epidermal Growth Factor Receptor; Erb-B2 Receptor Tyrosine Kinase 1; ERBB1; HER1
Production details: Cells were established by infection of ZR-75-1 cells with cell free supernatant of NT/HERc virus producing psi-2 cells for 17h in the presence of 8uM polybrene. Clones were selected in media containing 1mg/ml G418 and expanded in estradiol containing media.
Parental cell line: ZR-75-1
Disease: Cancer
Cat. #: 154629
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Breast cancer
Research Fields: Cancer; Drug development
Organism: Human
Tissue: Breast
Model: Cancer Model
Cancer Types In Detail: Mammary ductal carcinoma
Format: Frozen
Storage conditions: Liquid Nitrogen
Shipping conditions: Dry ice
Growth medium: RPMI 1640 medium supplemented with 10% heat-inactivated bovine serum (RBCS) and 1 nM 17?-estradiol
Mycoplasma free: Yes
Biosafety level: 1
References:

van Agthoven et al. 1992. Cancer Res. 52(18):5082-8. PMID: 1516065.

Images

View Gallery

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.